Navigation Links
Keryx Biopharmaceuticals, Inc. Announces Michael P. Tarnok as Interim Chairman and Chief Executive Officer
Date:4/23/2009

NEW YORK, April 23 /PRNewswire-FirstCall/ -- Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX) today announced the appointment of Michael P. Tarnok to be its interim Chairman and Chief Executive Officer, replacing Michael S. Weiss, effective immediately.

Mr. Tarnok, age 54, has served on Keryx's Board of Directors since September 2007. Mr. Tarnok spent the majority of his career at Pfizer Inc., which he joined in 1989 as Finance Director -- US Manufacturing. From 2000-2007, Mr. Tarnok served as Senior Vice President, Finance in Pfizer's US Pharmaceuticals Division. In this position, Mr. Tarnok handled all finance responsibilities for the division, including contracting, trade management, forecasting of significant product launches and Sarbanes-Oxley compliance. Prior to joining Pfizer, Mr. Tarnok worked primarily in financial disciplines for ITT Rayonier, Inc., Celanese Corporation and Olivetti Corporation of America.

ABOUT KERYX BIOPHARMACEUTICALS, INC.

Keryx Biopharmaceuticals is focused on the acquisition, development and commercialization of medically important, novel pharmaceutical products for the treatment of life-threatening diseases, including renal disease and cancer. Keryx is developing Zerenex(TM) (ferric citrate), an oral, iron-based compound that has the capacity to bind to phosphate and form non-absorbable complexes. Zerenex is currently in Phase 2 clinical development for the treatment of hyperphosphatemia (elevated phosphate levels) in patients with end-stage renal disease, or ESRD. The Company is also developing KRX-0401 (perifosine), a novel, potentially first-in-class, oral anti-cancer agent that modulates Akt, a protein in the body associated with tumor survival and growth. KRX-0401 also modulates a number of other key signal transduction pathways, including the JNK and MAPK pathways, which are pathw
'/>"/>

SOURCE Keryx Biopharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Keryx Biopharmaceuticals to Present at Bank of America Investment Conference
2. Keryx Biopharmaceuticals, Inc. Announces Appointment of Michael P. Tarnok to Board of Directors
3. Keryx Biopharmaceuticals, Inc. Announces Conference Call to Discuss Strategic Alliance
4. Keryx Biopharmaceuticals, Inc. Enters into Licensing Agreement with Japan Tobacco and Torii Pharmaceutical for Development and Commercialization of Hyperphosphatemia Drug in Japan
5. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Third Quarter 2007 Financial Results on Thursday, October 25, at 8:30 A.M. EDT
6. Keryx Biopharmaceuticals, Inc. Announces Third Quarter 2007 Financial Results
7. Keryx Biopharmaceuticals Announces Upcoming Corporate Presentations
8. Keryx Biopharmaceuticals Announces Additions to Management Team
9. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Fourth Quarter and Year-End 2007 Financial Results on Monday, February 25, at 8:30 A.M. EST
10. Keryx Biopharmaceuticals, Inc. Announces Fourth Quarter and Year-End 2007 Financial Results
11. Keryx Biopharmaceuticals Announces that SUN-MICRO Phase 3 Clinical Trial Fails to Meet Primary Efficacy Endpoint
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/20/2014)... GUELPH, ON , Oct. 20, 2014 /PRNewswire/ - BIOREM Inc. ... totalling $1.7 million which brings Q3 orders to $5.8 million and ... odour control projects in North America and ... "We continue to bid new projects at record levels," said ... values were higher at the end of Q3 than they have ...
(Date:10/20/2014)... 2014  GenVec, Inc. (NASDAQ: GNVC ) today ... from its board of directors effective on October 24, 2014.  ... served as its chairman from June 2006 to November 2013.  ... Corporate Governance and Audit Committees of the board.  ... of dedicated service to GenVec, and its stockholders," said ...
(Date:10/20/2014)... N.J. (PRWEB) October 20, 2014 ... the Sidney Kimmel Cancer Center at Thomas Jefferson ... , Through the Strategic Alliance Partnership program, ... OncLive will collaborate to raise awareness of the ... treatment, and other projects. Clinicians and other health ...
(Date:10/20/2014)... Tigard, OR (PRWEB) October 20, 2014 ... to participate in an investigational study of donor stem ... nationally in stem cell therapy and has performed clinical ... of this study is to determine if a single ... arthritically affected joints can help reduce pain and inflammation ...
Breaking Biology Technology:Zola P. Horovitz To Retire From GenVec Board 2Sidney Kimmel Cancer Center at Thomas Jefferson University Partners With OncLive 2Sidney Kimmel Cancer Center at Thomas Jefferson University Partners With OncLive 3Cascade Veterinary Referral Center Seeks Candidates for an Investigational Study of Stem Cells for Dogs with Arthritis 2
... , , , , Agencourt offers ... identification of SNP loci. Our SeeSNP service , is based ... to sequence over 20 million Phred20 bases a day. Features that set our ... , SPRItechnology for increased sequencing performance and ...
... , , , , , , ... throughput capacity of, 25,000 end reads per day. The key features of our ... Industry leading sequence quality , ... Fully-automated, GLP-compliant facility , , ...
... , , , , , ... of purifying amplicons as small as 100bp. AMPure yields high quality PCR , ... or filtration steps. The protocol can be easily automated or performed , ... , EFFICIENT PCR PURIFICATION ...
Cached Biology Technology:SEESNP DISCOVERY 2END SEQUENCING 2AMPURE PURIFICATION SYSTEM 2AMPURE PURIFICATION SYSTEM 3
(Date:10/16/2014)... women experienced improvements in vaginal atrophy, with no ... after 12 weeks of daily 10 milligram (mg) ... supplement previously shown to help relieve certain menopause ... reported in a poster at the North American ... "These data documented improved vaginal epithelium, without significant ...
(Date:10/15/2014)... ,Models of Life, is a non-traditional biophysics textbook and ... book is a journey of discovery into biological systems ... and biological regulation. It is about how our genes ... between the billions of cells in an organism. It ... between principles, which can be found on both large ...
(Date:10/15/2014)... NXT-ID, Inc. (NASDAQ: NXTD and NXTDW) ... growing mobile commerce market releases photos and video of the recent ... October 13 th . Gino Pereira , ... angel investor Mr. Chad A. Verdi rang the bell.  ... his investors and employees "for their work and dedication in bringing ...
Breaking Biology News(10 mins):S-equol supplements associated with improved measures of reproductive health in postmenopausal women 2New book about life as seen from physics 2Photo Release: NXT-ID Inc. Rings Opening Bell of the NASDAQ Stock Market October 13th 2Photo Release: NXT-ID Inc. Rings Opening Bell of the NASDAQ Stock Market October 13th 3
... Nov. 6, 2013 /PRNewswire-iReach/ -- IdentiSys Inc., North ... identification, card issuance, emergency response, and access control security ... the world,s leader in Customer and Patient Experience Management ... system from Qmatic to the marketplace and will be ...
... phytochemicals called polyphenols, which have been reported by a growing ... health benefits. A new study by researchers at the University ... This new research, published today in the journal ... long-term wild blueberry diets may help improve or prevent pathologies ...
... written to describe proteins, as the M. C. Escher-esque ... to carry out its specific responsibilities. Technology,s workhorse for ... a beam of x-rays sent through a crystallized protein ... pattern of dots that can be reconstructed by computer ...
Cached Biology News:IdentiSys brings Qmatic Q-Guide Queuing Systems to the North American market 2IdentiSys brings Qmatic Q-Guide Queuing Systems to the North American market 3Health benefits of wild blueberries abound: Study 2Bringing out the best in X-ray crystallography data 2
Rabbit polyclonal to VPAC2 ( Abpromise for all tested applications). entrezGeneID: 7434 SwissProtID: P41587...
... Synthetic peptide corresponding ... Antigen Family: ... Antigen Subfamily: not ... Recommended Storage: Long ...
... The Experion HighSens analysis kit for ... required to perform high-sensitivity RNA analysis (at ... system. This kit includes 25 RNA HighSens ... gel, 2 x 20 microliters RNA HighSens ...
... The Staccato Application Series are ... systems designed to provide fast and ... Utilizing proven and robust "automation-friendly" building ... solutions that cost less than conventional ...
Biology Products: